The microarray analyses identified the triple-negative breast cancer (ER-, PR- and HER2-negative) as a clinically heterogeneous malignancy and the most aggressive BCa subtype that is characterised by high rates of tumour recurrence and poor overall survival. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.